Transmission Assessment Survey Guidelines
Survey Sample Builder
Generic Protocol to Analyze the Costs of an MDA Program for the Elimination of Lymphatic Filariasis
We are pleased to share this protocol developed by the LF Support Center to facilitate cost analyses of the mass drug administration component of LF elimination programs. The protocol was developed to collect data systematically in a number of countries to provide comparable results across programs. The protocol presents general guidance for developing and conducting a cost analysis, and it is expected that each country will adapt the protocol to reflect its own program. The individual country results and multi-country results are vital to program planners and others for use in advocacy, program accountability, and program planning.
Cost analysis allows for informed budgeting of limited resources for the greatest impact. The results of cost analyses of LF programs can provide information for government policymakers, program managers, and LF advocates in countries with existing programs and for those interested in setting up LF programs, as well as, private, bilateral and multilateral donors. Collecting data about costs and analyzing it in the context of program activities provides information about efficiency in achieving results and program sustainability. Cost data from LF programs can project future program needs and stimulate the development of new and better ways of carrying out activities.
The generic protocol guides users through the steps of framing the analysis, identifying costs, collecting and organizing data, analyzing data and presenting results. The generic protocol has two sections, the handbook (the Microsoft Word document above) and the worksheets. The set of blank pre-formatted Excel worksheets with embedded formulas for organizing and analyzing data is available on request from email@example.com.
Reimbursement Information for Meeting Participants
Fundraising and Advocacy
A 16-page brochure detailing LF, the Global Alliance, the successes and the challenges of the program to eliminate LF is available as a PDF in English and French.
To request copies of the brochure, please contact us at firstname.lastname@example.org.
Annually over 100 million women will be treated with albendazole and Mectizan® through national LF elimination programs. The immediate clinical effects of albendazole and ivermectin extend beyond the prevention of LF and include the treatment of intestinal parasite infections. This booklet highlights the research documenting the significant benefits of treating intestinal parasites, such as lower mortality from severe anemia, lower incidence of low-birth-weight babies and better earning capacity for mothers. These benefits come at no additional cost to the health system or individual since albendazole and ivermectin are distributed as mainstay drugs of the LF elimination program.
Annually, more than 200 million children will be treated for intestinal parasites through national LF Elimination programs. The benefits from using albendazole and ivermectin to eliminate LF are multiplied for the millions of children also at-risk or suffering from intestinal parasites. This booklet highlights the research documenting the significant benefits of treating intestinal parasites. These benefits come at no additional cost to the health system or individual since albendazole and ivermectin are distributed as mainstay drugs of the LF elimination program.
The Fundraising and Advocacy Toolkit
Developed by the Global Alliance, this toolkit was given to participants at fundraising workshops in Atlanta and Manila. It is now available in English and French here on the internet for downloading documents, journal articles and pictures including background information about LF and the global program, advocacy strategies, and fundraising guidelines.